SNP•its Study Summaries

SNPits logoThe SNP•its editorial team monitors leading medicine, pharmacy, pharmacogenomics, and genomic medicine journals on a daily basis. We evaluate each pharmacogenomics article for clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for SNP•its Study Summaries, which discuss findings and clinical implications of pharmacogenomics studies in the context of the larger evidence base. Browse our study summaries via the feed below or our topical literature digests.

SummariesSubscribe to RSS Feed

AHA 2016: UF’s Larisa Cavallari presents findings on improving cardiac outcomes with genetic testing

Nov 16th, 2016

This NIH-funded, UF-led study showed that a genetic test can significantly reduce the risk of adverse cardiac events for heart stent patients by helping identify the best antiplatelet medication for each patient.

Drug–drug and drug–gene interactions in a large population undergoing pharmacogenetic testing

Feb 28th, 2016

As pharmacogenetic data are increasingly being incorporated into the patient care decision making process, additional information is needed to inform clinician strategies and priorities. An important step in obtaining these […]

TPMT genotyping: Decreased hematologic adverse events in IBD

Feb 1st, 2016

Daniel Beylik, Pharm.D. Candidate, Class of 2016 Thiopurine agents such as 6-mercaptopurine or azathioprine are used in patients with inflammatory bowel disease (IBD) as well as some pediatric cancers (i.e., […]

American College of Medical Genetics revises position statement on direct-to-consumer genetic testing

Jan 15th, 2016

In response to increasing availability of genetic testing opportunities and consumer demand, the American College of Medical Genetics (ACMG) has updated its 2008 position statement on direct-to-consumer genetic testing. In […]

Clopidogrel: Effect of esomeprazole on platelet activity, clinical outcomes

Jan 15th, 2016

Daryl Nnani, PharmD Candidate 2016 Albany College of Pharmacy and Health Sciences Dual antiplatelet therapy with aspirin and clopidogrel is indicated for the prevention of atherothrombotic events in patients with […]

Celecoxib: CYP2C9 variability influences colorectal adenoma prevention

Jan 4th, 2016

Daniel Beylik, Pharm.D. Candidate, Class of 2016 Celecoxib is a selective COX-2 NSAID. This agent has a potentially lower incidence of gastrointestinal adverse effects as compared with nonselective COX-2 inhibitors, […]

Informatics: Variability in EHR display of genomic data influences clinical use

Jul 17th, 2015

Dyson Wake, PharmD As precision medicine advances and increasing amounts of genomic and genetic data are incorporated into the electronic health record (EHR), needs for storing, accessing, and displaying this […]

CPIC authors respond to CYP2D6–codeine clinical perspective article

Jun 1st, 2015

The Clinical Pharmacogenetics Implementation Consortium (CPIC) published guidelines for use of codeine in patients with variable CYP2D6 metabolism in January 2014. These guidelines recommended a codeine alternative in CYP2D6 ultrarapid […]

New Lancet analysis supports benefit of pharmacogenomic testing for warfarin

May 15th, 2015

CYP2C9 and VKORC1 genotypes identified individuals who required lower doses of warfarin and were more likely to be over-anticoagulated, according to a recent analysis of the ENGAGE AF–TIMI 48 trial […]

ASHP releases statement on pharmacist’s role in clinical pharmacogenomics

Apr 1st, 2015

The American Society of Health System Pharmacists (ASHP) published a position statement on the pharmacist’s role in clinical pharmacogenomics in the April 2015 edition of the American Journal of Health-System […]

Case report: Tramadol-associated respiratory depression in CYP2D6 ultrarapid metabolizer

Mar 1st, 2015

Tramadol is metabolized through numerous pathways, including oxidation by the CYP2D6 enzyme to O-desmethyltramadol, which is primarily responsible for its analgesic effects. Although it has been documented that CYP2D6 genetic […]

JAMA: Vincristine peripheral neuropathy linked to CEP72 variability

Feb 25th, 2015

Vincristine is a widely used cytotoxic agent for cancer treatment in adults and children. A significant portion of patients treated with vincristine experience dose-limiting neuropathies including pain, sensory, and motor […]

Tagged as: ,